Skin diseases are the fourth leading cause of health afflictions, affecting nearly 900 million people worldwide. It’s not surprising, then, that there has recently been a noticeable increase in dermatology drug development. There are currently thousands of dermatology clinical trials planned or already launched, including a variety of programs investigating innovative, targeted therapies.
Much of the development progress in dermatology, however, has been made in a small subset of diseases, such as melanoma, psoriasis, and atopic dermatitis. There is still a significant unmet need for safe and effective treatments for the vast majority of the more than 3,000 known skin disorders.